CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.
Jag Srai talks to Research Horizons magazine
CMAC Hub academic Dr Jag Srai, leader of the REMEDIES Commercial Supply Chain, has an article in Research Horizons magazine and on the Cambridge website.... more
Images of Research 2017 Winner
CMAC’s Monika Warzecha is the overall winner in this year’s Images of Research at Strathclyde. Her image, in the ‘Advanced Manufacturing and Materials’ category, won via a public vote..... more
Press: Article in Pharmaceutical Online
CMAC’s John Mulgrew has published an article in Pharmaceutical Online about the REMEDIES project and CMAC’s contribution to it. .... more